M. Demeo

发表

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.

E. Winer, L. Carey, J. Garber, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients

E. Winer, C. Paweletz, R. Jain, 2016, The oncologist.

HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial.

E. Winer, L. Trippa, K. Polyak, 2019, Journal of Clinical Oncology.

Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial

E. Winer, R. Gelber, L. Trippa, 2022, NPJ breast cancer.

Abstract GS1-05: TBCRC 033: A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)

E. Winer, L. Trippa, R. Bose, 2020 .

Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial)

E. Winer, Minetta C. Liu, R. Bose, 2021, Breast Cancer Research and Treatment.

Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT)

V. Valero, A. Wolff, H. Burstein, 2022, npj Breast Cancer.

Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab.

E. Winer, L. Trippa, K. Polyak, 2021, Cancer discovery.

TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).

E. Winer, J. Garber, A. Wolff, 2020 .

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer.

M. Ellis, C. Hudis, L. Carey, 2023, The New England journal of medicine.

Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial

R. Gelber, L. Trippa, Minetta C. Liu, 2022, npj Breast Cancer.

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

E. Winer, R. Gelber, L. Trippa, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Local therapy outcomes and toxicity from the (anonymized for review) trial: A phase II randomized trial of adjuvant trastuzumab emtansine vs. paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer

E. Winer, J. Bellon, H. Burstein, 2022, International Journal of Radiation Oncology, Biology, Physics.

Abstract GS3-06: GS3-06 Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer

A. DeMichele, H. Burstein, M. Regan, 2023, Cancer Research.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.

M. Ellis, C. Hudis, L. Carey, 2023, The Lancet. Oncology.

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer

A. DeMichele, H. Burstein, K. Miller, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.